Nerve growth factor mutant

Abstract

Provided is a nerve growth factor mutant, wherein the nerve growth factor mutant is an amino acid sequence as shown by any one of SEQ ID No: 3 to SEQ ID No: 21 in the sequence listing. The advantage of the nerve growth factor mutant lies in that the mutation of a nerve growth factor can alleviate side effects such as pain, falling within the field of biological pharmacy.

1 . (canceled) 
     
     
         2 . A nerve growth factor mutant comprising Lys88Gly with reference to the amino acid positions set forth in a wild-type human nerve growth factor. 
     
     
         3 . The nerve growth factor mutant according to  claim 2 , the wild-type human nerve growth factor mutant comprises an amino acid sequence of SEQ ID No: 2. 
     
     
         4 . The nerve growth factor mutant according to  claim 2 , wherein the nerve growth factor mutant comprising Lys88Gly has an amino acid sequence of SEQ ID No: 15. 
     
     
         5 . The nerve growth factor mutant according to  claim 2 , further comprising a chemical modification. 
     
     
         6 . The nerve growth factor mutant according to  claim 5 , wherein the chemical modification is PEGylation. 
     
     
         7 . The nerve growth factor mutant according to  claim 2 , wherein the nerve growth factor mutant is fused to a protein. 
     
     
         8 . The nerve growth factor mutant according to  claim 7 , wherein the protein is a human albumin, a fragment of a human albumin, an Fc moiety of an immunoglobulin, or a fragment of an Fc moiety of an immunoglobulin. 
     
     
         9 . The nerve growth factor mutant according to  claim 7 , wherein the nerve growth factor mutant is fused to the protein by fusing a C-terminal of the nerve growth factor mutant with a N-terminal of an albumin or an Fc protein directly or via a peptide linker. 
     
     
         10 . A pharmaceutical composition, comprising a pharmaceutically acceptable excipient, and a nerve growth factor mutant of  claim 2 . 
     
     
         11 . The pharmaceutical composition according to  claim 10 , wherein the pharmaceutical composition is formulated for injection. 
     
     
         12 . A method of using the nerve growth factor mutant according to  claim 2  to treat or inhibit a nervous system disease comprising:
 administering the nerve growth factor mutant according to  claim 2  to a subject in need thereof. 
 
     
     
         13 . The method of  claim 12 , wherein the nervous system disease is a disease associated with neuronal degeneration or injury in the central and/or peripheral nervous system. 
     
     
         14 . A method of using the nerve growth factor mutant according to  claim 2  to reduce the weight of a subject comprising:
 administering the nerve growth factor mutant according to  claim 2  to a subject in need thereof. 
 
     
     
         15 . A method of using the nerve growth factor mutant according to  claim 2  to provide a long-acting nerve growth factor to a subject comprising:
 administering the nerve growth factor mutant according to  claim 2  to a subject in need thereof.